Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Moody's
MCO
5
Jefferies Financial
JEF
CA Stock MarketDetailed Quotes
ONC Oncolytics Biotech Inc
- 0.750
- -0.030-3.85%
15min DelayMarket Closed May 2 16:00 ET
64.95MMarket Cap-1.83P/E (TTM)
0.780High0.750Low39.85KVolume0.780Open0.780Pre Close30.29KTurnover2.08052wk High0.05%Turnover Ratio86.60MShares0.67052wk Low-0.41EPS TTM62.66MFloat Cap204.250Historical HighLossP/E (Static)83.55MShs Float0.480Historical Low-0.41EPS LYR3.85%Amplitude--Dividend TTM10.87P/B1Lot Size--Div YieldTTM
About Oncolytics Biotech Inc Company
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Company Profile
SymbolONC
Company NameOncolytics Biotech Inc
Founded1998
MarketTSE
Employees28
Fiscal Year Ends12-31
Address322 11th Avenue S.W Suite 804
CityCalgary
CountryCAN
Zip CodeT2R 0C5
Phone+1 403 670-7377
Company Executives
- Name
- Position
- Salary
- Wayne Pisano
- Chairman of the Board and Interim Chief Executive Officer
- 134.58K
- Kirk J. Look
- Chief Financial Officer
- 1.01M
- Dr. Thomas C. Heineman, M.D.
- Chief Medical Officer
- 1.17M
- Amy G. Levin
- Vice President, Clinical Operations
- 654.71K
- Allison Hagerman, P. Eng.
- Vice President, Product Development
- 635.84K
- Christophe Degois
- Vice President, Business Development
- --
- Patricia S. Andrews
- Director
- 108.36K
- Deborah M. Brown
- Independent Director
- 104.79K
- Angela Holtham
- Independent Director
- 110.55K
- Jonathan M. Rigby
- Independent Director
- 87.52K
- James T. Parsons
- Independent Director
- 94.72K
- Dr. Bernd R. Seizinger, M.D.,PhD
- Independent Director
- 103.35K
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts